Adrian Ling, MB BS. Rosie Dawkins, BMedSc(Hons), MB BS, MPH. Michael Bailey, BSc(Hons), MSc(Stats), PhD. Michael Leung, MB BS, FRACS. Heather Cleland, MB BS, FRACS. Jonathan Serpell, MBBS, M.D., FRACS, FACS. John W. Kelly, M.D., FACD.
Short-term morbidity associated with sentinel lymph node biopsy in cutaneous malignant melanoma
Version of Record online: 17 DEC 2009
© 2009 The Authors. Journal compilation © 2009 The Australasian College of Dermatologists
Australasian Journal of Dermatology
Volume 51, Issue 1, pages 13–17, February 2010
How to Cite
Ling, A., Dawkins, R., Bailey, M., Leung, M., Cleland, H., Serpell, J. and Kelly, J. (2010), Short-term morbidity associated with sentinel lymph node biopsy in cutaneous malignant melanoma. Australasian Journal of Dermatology, 51: 13–17. doi: 10.1111/j.1440-0960.2009.00575.x
The corresponding author is not a recipient of a research scholarship.
The paper is not based on a previous communication to a society or meeting.
- Issue online: 1 FEB 2010
- Version of Record online: 17 DEC 2009
- Submitted 4 September 2009; accepted 21 September 2009.
- body mass index;
- malignant melanoma;
- sentinel lymph node biopsy
Guidelines for the surgical treatment of cutaneous primary malignant melanoma are well established; however, the approach to the treatment of the regional lymph nodes remains more controversial. In many centres, sentinel lymph node biopsy has been adopted as routine in the treatment of malignant melanoma for prognostic purposes, as it is not of proven therapeutic benefit. The Multicentre Selective Lymphadenectomy Trial II aims to determine the comparative benefits of subsequent completion lymphadenectomy versus observation in those found to have a positive sentinel node biopsy. Until results are available, the risks of the procedure must be weighed against the value of prognostic information gained from performing a sentinel node biopsy. In this retrospective analysis of sentinel lymph node biopsies at our institution, we show that in general, short-term morbidity associated with this procedure is low, but that morbidity is higher in a subgroup of people with higher weight or body mass index, and in those whose biopsy is located in the groin.